About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Tg(Kit*D814V)3Roer
transgene insertion 3, Axel Roers
MGI:4942359
Summary 4 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Tg(CMV-cre)1Cgn/0
Tg(Kit*D814V)3Roer/0 		involves: BALB/cJ * C57BL/6 MGI:4942366
cn2
 		Tg(Cma1-cre)ARoer/0
Tg(Kit*D814V)3Roer/0 		involves: C57BL/6 MGI:4942364
cn3
 		Tg(Kit*D814V)3Roer/0
Commd10Tg(Vav1-icre)A2Kio/Commd10+ 		involves: C57BL/6 * C57BL/10 * CBA/Ca MGI:4942368
cn4
 		Tg(Kit*D814V)3Roer/0
Tg(Mx1-cre)1Cgn/0 		involves: C57BL/6 * CBA MGI:4942362


Genotype
MGI:4942366
cn1
Allelic
Composition		 Tg(CMV-cre)1Cgn/0
Tg(Kit*D814V)3Roer/0
Genetic
Background		 involves: BALB/cJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CMV-cre)1Cgn mutation (6 available)
Tg(Kit*D814V)3Roer mutation (0 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
decreased survivor rate ( J:169611 )
• only about 25% of mice survive to adulthood
• surviving mice show signs of spontaneous regression of the hyperproliferative dysregulation of erythropoiesis
neonatal lethality, incomplete penetrance ( J:169611 )
• rapid lethality in about 75% of neonatal mice

hematopoietic system
abnormal erythropoiesis ( J:169611 )
• mice appear to die of hyperproliferative dysregulation of erythropoiesis
increased nucleated erythrocyte cell number ( J:169611 )
• dramatic dysregulation of hematopoiesis characterized by excessive numbers of nucleated cells in the peripheral blood
• increase in nucleated cells is primarily the result of a population of small blastic cells with sparse cytoplasm
increased mast cell number ( J:169611 )
• survivors develop mastocytosis similar to that in mice carrying Tg(Kit*D814V)3Roer and Tg(Mx1-cre)1Cgn
abnormal erythrocyte physiology ( J:169611 )
• increase in the number of nuclear shadows in blood smears indicates the presence of cells with increased mechanical fragility

liver/biliary system
abnormal liver morphology ( J:169611 )
• most of the liver parenchyma is replaced with Ter119+ cells

immune system
increased mast cell number ( J:169611 )
• survivors develop mastocytosis similar to that in mice carrying Tg(Kit*D814V)3Roer and Tg(Mx1-cre)1Cgn




Genotype
MGI:4942364
cn2
Allelic
Composition		 Tg(Cma1-cre)ARoer/0
Tg(Kit*D814V)3Roer/0
Genetic
Background		 involves: C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
hematopoietic system
increased mast cell number ( J:169611 )
• accumulation of mast cells in the skin and in some cases also in the spleen
• disease symptoms occur later and disease progression is slower compared to mice carrying Tg(Kit*D814V)3Roer and Tg(Mx1-cre)1Cgn
• develop mastocytosis similar to that in mice carrying Tg(Kit*D814V)3Roer and Tg(Mx1-cre)1Cgn

neoplasm
increased skin tumor incidence ( J:169611 )
• mast cell tumors are seen in some mice

integument
increased skin tumor incidence ( J:169611 )
• mast cell tumors are seen in some mice

immune system
increased mast cell number ( J:169611 )
• accumulation of mast cells in the skin and in some cases also in the spleen
• disease symptoms occur later and disease progression is slower compared to mice carrying Tg(Kit*D814V)3Roer and Tg(Mx1-cre)1Cgn
• develop mastocytosis similar to that in mice carrying Tg(Kit*D814V)3Roer and Tg(Mx1-cre)1Cgn

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
mastocytosis DOID:350 OMIM:154800
 J:169611




Genotype
MGI:4942368
cn3
Allelic
Composition		 Tg(Kit*D814V)3Roer/0
Commd10Tg(Vav1-icre)A2Kio/Commd10+
Genetic
Background		 involves: C57BL/6 * C57BL/10 * CBA/Ca
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Commd10Tg(Vav1-icre)A2Kio mutation (3 available); any Commd10 mutation (24 available)
Tg(Kit*D814V)3Roer mutation (0 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
neonatal lethality ( J:169611 )
• similar to the phenotype in mice carrying Tg(CMV-cre)1Cgn and Tg(Kit*D814V)3Roer




Genotype
MGI:4942362
cn4
Allelic
Composition		 Tg(Kit*D814V)3Roer/0
Tg(Mx1-cre)1Cgn/0
Genetic
Background		 involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Kit*D814V)3Roer mutation (0 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
premature death ( J:169611 )
• 1 pIpC treated mouse was euthanized due to severe disease at 12 weeks of age

digestive/alimentary system
abnormal feces composition ( J:169611 )
• diarrhea with bloody feces is seen in mice with intestinal inflammation
diarrhea ( J:169611 )
• in mice with intestinal inflammation
rectal prolapse ( J:169611 )
• in mice with intestinal inflammation
large intestinal inflammation ( J:169611 )
• in a few mice, regardless of pIpC treatment
colitis ( J:169611 )
• rare

hematopoietic system
enlarged spleen ( J:169611 )
• in mice with leukemia
abnormal mast cell morphology ( J:169611 )
• most of the mast cells in pIpC treated mice with mastocytosis are round with some degree of hypergranulation and only few spindle shaped cells are seen
increased mast cell number ( J:169611 )
• mice treated with 3 injections of pIpC every second day at 4 to 10 weeks of age develop diffuse mastocytosis by 13 - 38 weeks of age
• pIpC treated mice display a variable increase in cutaneous mast cell numbers
• in some pIpC treated mice accumulations of mast cells are seen in the lymph nodes
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
abnormal bone marrow cell physiology ( J:169611 )
• bone marrow cells are unable to engraft in nonirradiated recipient mice

neoplasm
increased skin tumor incidence ( J:169611 )
• some pIpC treated mice develop large numbers of dermal mast cell tumors of variable size
• in a few mice these tumors are macroscopically visible
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice
increased leukemia incidence ( J:169611 )
• some mice, regardless of pIpC treatment, develop a condition resembling B-lymphoblastic leukemia

growth/size/body
weight loss ( J:169611 )
• in mice with intestinal inflammation
enlarged spleen ( J:169611 )
• in mice with leukemia

integument
increased skin tumor incidence ( J:169611 )
• some pIpC treated mice develop large numbers of dermal mast cell tumors of variable size
• in a few mice these tumors are macroscopically visible
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice

immune system
large intestinal inflammation ( J:169611 )
• in a few mice, regardless of pIpC treatment
colitis ( J:169611 )
• rare
enlarged spleen ( J:169611 )
• in mice with leukemia
abnormal mast cell morphology ( J:169611 )
• most of the mast cells in pIpC treated mice with mastocytosis are round with some degree of hypergranulation and only few spindle shaped cells are seen
increased mast cell number ( J:169611 )
• mice treated with 3 injections of pIpC every second day at 4 to 10 weeks of age develop diffuse mastocytosis by 13 - 38 weeks of age
• pIpC treated mice display a variable increase in cutaneous mast cell numbers
• in some pIpC treated mice accumulations of mast cells are seen in the lymph nodes
• mice not treated with pIpC develop phenotypes similar to those in pIpC injected mice

Mouse Models of Human Disease
 DO ID OMIM ID(s) Ref(s)
mastocytosis DOID:350 OMIM:154800
 J:169611




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory